Experience with carbon-11 choline positron emission tomography in prostate carcinoma

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Jörg Kotzerke - , Ulm University (Author)
  • Jürgen Prang - , Ulm University (Author)
  • Bernd Neumaier - , Ulm University (Author)
  • Björn Volkmer - , Ulm University (Author)
  • Albrecht Guhlmann - , Ulm University (Author)
  • Klaus Kleinschmidt - , Ulm University (Author)
  • Richard Hautmann - , Ulm University (Author)
  • Sven N. Reske - , Ulm University (Author)

Abstract

We investigated the potential of carbon-11 choline positron emission tomography (PET) for the detection of lymph node and bone metastases in prostate cancer. A total of 23 patients were studied (known metastases: 8; suspicion of metastases: 3; primary staging: 12). Whole-body PET imaging was performed 5 min after injection of the tracer and completed within 1 h. Focally increased tracer uptake in bone or abdominal lymph node regions was interpreted as representing tumour involvement. All known bone and lymph node metastases could be recognized by [11C]choline PET. One out of ten negative scans for primary staging was false-negative (lymph node <1 cm) and one out of two positive scans was false-positive with regard to lymph node involvement (focal bowel activity). It is concluded that [11C]choline PET is a promising new tool for the primary staging of prostate cancer, with lymph node and bone metastases demonstrating high tracer uptake. Therapeutic management could be influenced by these results in that the technique may permit avoidance of surgical lymph node exploration.

Details

Original languageEnglish
Pages (from-to)1415-1419
Number of pages5
JournalEuropean Journal of Nuclear Medicine
Volume27
Issue number9
Publication statusPublished - 2000
Peer-reviewedYes
Externally publishedYes

External IDs

PubMed 11007527

Keywords

Sustainable Development Goals

Keywords

  • Choline, Positron emission tomography, Prostate cancer, Staging

Library keywords